Table II.
Treatment outcome of the three platelet groups in the 1,501 nasopharyngeal carcinoma patients.
| Platelet count | Five-year OS, % | P-valuea | Five-year LRFS, % | P-valuea | Five-year DMFS, % | P-valuea |
|---|---|---|---|---|---|---|
| CCRT patients (n=412) | 0.005 | 0.153 | 0.036 | |||
| Low | 57.9 | 76.0 | 82.5 | |||
| Moderate | 76.7 | 83.4 | 89.5 | |||
| High | 60.7 | 72.4 | 77.4 | |||
| RT patients (n=1089) | 0.005 | 0.224 | <0.001 | |||
| Low | 79.3 | 81.8 | 93.5 | |||
| Moderate | 83.2 | 86.9 | 94.9 | |||
| High | 76.4 | 85.5 | 86.0 |
a
Determined by joint analysis.
OS, overall survival; LRFS, local-regional recurrence-free survival; DMFS, distant metastasis-free survival; CCRT, concurrent chemoradiotherapy; RT, radiotherapy alone.